Axovant Announces Negative Topline Results of Intepirdine Phase 3 MINDSET Trial in Alzheimer's Disease
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- Wall St set for higher open as AI stocks rise, oil slides
Axovant Sciences (AXON) PT Lowered to $25 at Cowen; Lewy Body Program Remains Focus
September 26, 2017 11:48 AM EDTCowen analyst Ritu Baral lowered his price target on Axovant Sciences (NASDAQ: AXON) to $25.00 (from $30.00) while maintaining an Outperform rating after the company reported the pivotal Ph3 MINDSET trial of intepirdine in Alzheimer's failed to meet its primary endpoint.
Baral notes... More
UPDATE: Piper Jaffray Downgrades Axovant Sciences (AXON) to Neutral
September 26, 2017 10:53 AM EDT(Updated - September 26, 2017 11:02 AM EDT)
(updated to add analyst comment)
Piper Jaffray downgraded Axovant Sciences (NASDAQ: AXON) from Overweight to Neutral with a price target of $9.00 (from $32.00).
Analyst Charles Duncan says the pipeline needs to be rebuild... More
Oppenheimer Downgrades Axovant Sciences (AXON) to Perform
September 26, 2017 10:48 AM EDTOppenheimer downgraded Axovant Sciences (NASDAQ: AXON) from Outperform to Perform.
For an analyst ratings summary and ratings history on Axovant Sciences click here. For more ratings news on Axovant Sciences click here.
Shares of Axovant Sciences closed at $24.25 yesterday.
... MoreUPDATE: Axovant Sciences (AXON) PT Lowered to $3 at Chardan Capital Markets
September 26, 2017 9:49 AM EDT(Updated - September 26, 2017 9:52 AM EDT)
(updated to add comments)
Chardan Capital Markets lowered its price target on Axovant Sciences (NASDAQ: AXON) to $3.00 (from $8.00) while maintaining a Sell rating after the company fails to demonstrate statistical significance on either co-primary endpoint (ADAS-Cog and ADCS-ADL) in the phase III MINDSET trial of intepirdine in mild-to-moderate... More
Baird Downgrades Axovant Sciences (AXON) to Neutral, $6 PT
September 26, 2017 9:38 AM EDTBaird downgraded Axovant Sciences (NASDAQ: AXON) from Outperform to Neutral with a price target of $6.00 (from $29.00) after the failure of the Phase 3 MINDSET study in Alzheimer's.
Analyst Brian Skorney commented, " There may be a reasonable argument to allow thesis drift here, given the... More
Axovant Sciences (AXON) Sinks 70% as Trading Resumes
September 26, 2017 7:32 AM EDTAxovant Sciences (NASDAQ: AXON) falls 70% to as trading resumes following trial failure.
Axovant Sciences (AXON) to Resume Trading at 7:30 AM ET
September 26, 2017 7:05 AM EDTAxovant Sciences (NASDAQ: AXON) to Resume Trading at 7:30 AM ET
... More